Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
10:02am, Wednesday, 21'st May 2025
Media Release COPENHAGEN, Denmark; May 21, 2025 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferie
Capital Increase in Genmab as a Result of Employee Warrant Exercise
12:01pm, Tuesday, 20'th May 2025
Company Announcement COPENHAGEN, Denmark; May 20, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 1,746 shares as a consequence of the exercise of employee warrants. The increase
Transactions in Connection with Share Buy-back Program
09:08am, Monday, 19'th May 2025
Company Announcement COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million sha
Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology
07:03am, Monday, 19'th May 2025
Genmab has promising proprietary antibody platforms and partnerships that have helped it transition from licensor to commercial-stage biotech. Their robust royalty stream from Darzalex and Kesimpta fu
Media Release COPENHAGEN, Denmark; May 14, 2025 Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient popu
Transactions in Connection with Share Buy-back Program
08:51am, Monday, 12'th May 2025
Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million sha
Genmab Announces Financial Results for the First Quarter of 2024
11:01am, Thursday, 08'th May 2025
May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025
Transactions in Connection with Share Buy-back Program
08:23am, Monday, 05'th May 2025
Company Announcement COPENHAGEN, Denmark; May 5, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shar
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food a
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ® FL-1 trial Full results from the
Transactions in Connection with Share Buy-back Program
08:16am, Monday, 28'th Apr 2025
Company Announcement COPENHAGEN, Denmark; April 28, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million s
Transactions in Connection with Share Buy-back Program
07:23am, Tuesday, 22'nd Apr 2025
Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million s
GMAB or RGEN: Which Is the Better Value Stock Right Now?
12:46pm, Wednesday, 16'th Apr 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value
Should Value Investors Buy Genmab (GMAB) Stock?
10:46am, Wednesday, 16'th Apr 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Genmab's Outlook Beyond Darzalex's Patent Cliff
07:36am, Tuesday, 15'th Apr 2025
Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company's robust late-stage pipeline could offset DAR
